{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.95","upperLimit":"1.00","value":"0.98"},{"groupId":"OG001","lowerLimit":"1.00","upperLimit":"1.00","value":"1.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"description":"Overall survival is defined as the time from randomization to death or date last known alive among all randomized patients in the phase III part of the study. Kaplan-Meier method was used to estimate the 2-year OS rate.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive lenalidomide PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm A (Lenalidomide; Phase III)"},{"description":"Patients undergo observation until progression to symptomatic myeloma.","id":"OG001","title":"Arm B (Observation; Phase III)"}],"paramType":"NUMBER","populationDescription":"All randomized patients in the phase III part of the study","reportingStatus":"POSTED","timeFrame":"Assessed every 3 months for 2 years","title":"2-year Overall Survival (OS) Rate (Phase III Secondary Endpoint)","type":"SECONDARY","unitOfMeasure":"proportion of participants"}